Shopping Cart
- Remove All
Your shopping cart is currently empty
Pomalidomide-PEG1-CO2H
🥰Excellent
Catalog No. T40024Cas No. 2139348-60-8
Alias Pomalidomide-PEG1-C2-COOH
Pomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.
Pomalidomide-PEG1-CO2H
🥰Excellent
Purity: 97.24%
Catalog No. T40024Alias Pomalidomide-PEG1-C2-COOHCas No. 2139348-60-8
Pomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $39 | In Stock | |
| 10 mg | $64 | In Stock | |
| 25 mg | $122 | In Stock | |
| 50 mg | $172 | In Stock | |
| 100 mg | $255 | In Stock | |
| 500 mg | $628 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Pomalidomide-PEG1-CO2H"
(S,R,S)-AHPC-PEG3-N3
VHL Ligand-Linker Conjugates 8, VH032-PEG3-N3, E3 ligase Ligand-Linker Conjugates 12
T179091797406-80-4
(S, R, S)-AHPC-PEG3-N3 (VHL Ligand-Linker Conjugates 8) is a synthesized E3 ligase ligand-linker conjugate. (S, R, S)-AHPC-PEG3-N3 incorporates the (S, R, S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology.
- $37
Size
QTY
Thalidomide-O-amido-PEG2-C2-NH2 TFA
E3 Ligase Ligand-Linker Conjugates 24 TFA, Cereblon Ligand-Linker Conjugates 10 TFA
T179181957235-75-4
Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.
- $29
Size
QTY
(S,R,S)-AHPC-PEG2-NH2 hydrochloride
VHL Ligand-Linker Conjugates 3 hydrochloride, VH032-PEG2-NH2 hydrochloride, E3 ligase Ligand-Linker Conjugates 6
T179242097973-72-1
(S,R,S)-AHPC-PEG2-NH2 hydrochloride (E3 ligase Ligand-Linker Conjugates 6) is a synthesized E3 ligase ligand-linker conjugate that includes the (S,R,S)-AHPC based VHL ligand and a 2-unit PEG linker used in the synthesis of PROTAC.
- $34
Size
QTY
Pomalidomide 4'-PEG3-azide
T398062271036-46-3
Pomalidomide 4'-PEG3-azide is a chemically synthesized E3 ligase ligand-linker conjugate that incorporates the cereblon ligand derived from Pomalidomide, along with a linker. This compound is utilized in the synthesis of iRucaparib-TP3 (Compound 3), an effective PARP1 degrader developed through the PROTAC strategy and derived from Rucaparib.
- $31
Size
QTY
Thalidomide-O-amido-C6-NH2 hydrochloride
T188162376990-31-5
Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.
- $54
Size
QTY
Thalidomide-O-amido-C4-NH2 TFA
E3 ligase Ligand-Linker Conjugates 19 TFA, Cereblon Ligand-Linker Conjugates 6 TFA
T77591799711-25-3
Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) is a synthesized compound that functions as an E3 ligase ligand-linker conjugate.
- $32
Size
QTY
Thalidomide-O-C6-NH2 hydrochloride
4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride
T400312245697-88-3
Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.
- $39
Size
QTY
Thalidomide-NH-C2-PEG3-OH
H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-
T93822140807-23-2
Thalidomide-NH-C2-PEG3-OH (H-Isoindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)-4-[[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethyl]amino]-) is an E3 ligase ligand-linker conjugate.
- $89
Size
QTY
Thalidomide-O-amido-PEG3-C2-NH2 TFA
E3 ligase Ligand-Linker Conjugates 14 TFA, Cereblon Ligand-Linker Conjugates 3 (TFA)
T77581957236-21-3
Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.
- $33
Size
QTY
Pomalidomide-C2-NH2 hydrochloride
T77612305369-00-8
Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate incorporating the Pomalidomide-based cereblon ligand and a linker used in [PROTAC] technology.
- $31
Size
QTY
Thalidomide 4'-ether-alkylC2-amine hydrochloride
halidomide-linker 6
T400302341840-99-9
Thalidomide 4'-ether-alkylC2-amine hydrochloride (halidomide-linker 6) is a synthesized E3 ligase ligand-linker conjugate.
- $30
Size
QTY
Thalidomide-NH-C4-NH-Boc
T188072093388-52-2
Thalidomide-NH-C4-NH-Boc is a synthesized conjugate used in PROTAC technology, combining a Thalidomide-based cereblon ligand with a linker.
- $30
Size
QTY
Select Batch
Purity:97.24%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Pomalidomide-PEG1-CO2H is a synthetic E3 ligase ligand-linker conjugate containing a Pomalidomide-based cereblon ligand and a 2-unit PEG linker. |
| In vitro | PROTACs contain two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, linked by a linker[1]. |
| Alias | Pomalidomide-PEG1-C2-COOH |
| Molecular Weight | 389.36 |
| Formula | C18H19N3O7 |
| Cas No. | 2139348-60-8 |
| Smiles | O=C1C=2C(C(=O)N1C3C(=O)NC(=O)CC3)=CC=CC2NCCOCCC(O)=O |
| Relative Density. | 1.508 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (256.8 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Pomalidomide-PEG1-CO2H | purchase Pomalidomide-PEG1-CO2H | Pomalidomide-PEG1-CO2H cost | order Pomalidomide-PEG1-CO2H | Pomalidomide-PEG1-CO2H chemical structure | Pomalidomide-PEG1-CO2H in vitro | Pomalidomide-PEG1-CO2H formula | Pomalidomide-PEG1-CO2H molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.